Duygu Duzgun

SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer

Docetaxel is a major therapeutic option for advanced prostate cancer, but the development of acquired resistance substantially limits its clinical efficacy. Although multiple mechanisms have been implicated in docetaxel resistance, the upstream regulatory pathways coordinating these phenotypes remain incompletely under...